Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Bellet Ezquerra, Meritxell; Ahmad, Faten; Villanueva, Rafael; Valdivia, Carolina; Palomino Doza, Julián; Ruiz, Ada; Gonzalez-Farre, Xavier; Adrover, Encarna; Azaro, Analía; Valls Margarit, Maria; Parra, Josep Lluís; Aguilar Company, Juan; Vidal Losada, Maria Jesús; Martin, Anastasi; Gavilá, Joaquín; Escrivá de Romaní, Santiago; Perelló, Antonia; Hernando, Cristina; Lahuerta, Ainhara; Zamora, Pilar; Reyes, Victoria; Alcalde, María; Masanas, Helena; Celiz, Pamela; Ruiz, Isabel; Gil Gil, Miguel; Seguí, Miquel A.; Peña, Lorena de la

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology a...

Descripción completa

Detalles Bibliográficos
Autores:	Bellet Ezquerra, Meritxell, Ahmad, Faten, Villanueva, Rafael, Valdivia, Carolina, Palomino Doza, Julián, Ruiz, Ada, Gonzalez-Farre, Xavier, Adrover, Encarna, Azaro, Analía, Valls Margarit, Maria, Parra, Josep Lluís, Aguilar Company, Juan, Vidal Losada, Maria Jesús, Martin, Anastasi, Gavilá, Joaquín, Escrivá de Romaní, Santiago, Perelló, Antonia, Hernando, Cristina, Lahuerta, Ainhara, Zamora, Pilar, Reyes, Victoria, Alcalde, María, Masanas, Helena, Celiz, Pamela, Ruiz, Isabel, Gil Gil, Miguel, Seguí, Miquel A., Peña, Lorena de la
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2019
País:	España
Institución:	Universidad de Barcelona
Repositorio:	Dipòsit Digital de la UB
OAI Identifier:	oai:diposit.ub.edu:2445/171556
Acceso en línea:	https://hdl.handle.net/2445/171556
Access Level:	acceso abierto
Palabra clave:	Càncer de mama Oncologia Breast cancer Oncology

id	ES_11b4e5edc2abd1245665ed9525ae2cd1
oai_identifier_str	oai:diposit.ub.edu:2445/171556
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medicationBellet Ezquerra, MeritxellAhmad, FatenVillanueva, RafaelValdivia, CarolinaPalomino Doza, JuliánRuiz, AdaGonzalez-Farre, XavierAdrover, EncarnaAzaro, AnalíaValls Margarit, MariaParra, Josep LluísAguilar Company, JuanVidal Losada, Maria JesúsMartin, AnastasiGavilá, JoaquínEscrivá de Romaní, SantiagoPerelló, AntoniaHernando, CristinaLahuerta, AinharaZamora, PilarReyes, VictoriaAlcalde, MaríaMasanas, HelenaCeliz, PamelaRuiz, IsabelGil Gil, MiguelSeguí, Miquel A.Peña, Lorena de laCàncer de mamaOncologiaBreast cancerOncologyDrug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.Sage Publications Ltd.2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/171556Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1177/1758835919833867Therapeutic Advances in Medical Oncology, 2019, vol. 11https://doi.org/10.1177/1758835919833867cc by-nc (c) Bellet et al., 2019http://creativecommons.org/licenses/by-nc/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1715562026-05-27T06:46:51Z
dc.title.none.fl_str_mv	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
spellingShingle	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication Bellet Ezquerra, Meritxell Càncer de mama Oncologia Breast cancer Oncology
title_short	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_full	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_fullStr	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_full_unstemmed	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_sort	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
dc.creator.none.fl_str_mv	Bellet Ezquerra, Meritxell Ahmad, Faten Villanueva, Rafael Valdivia, Carolina Palomino Doza, Julián Ruiz, Ada Gonzalez-Farre, Xavier Adrover, Encarna Azaro, Analía Valls Margarit, Maria Parra, Josep Lluís Aguilar Company, Juan Vidal Losada, Maria Jesús Martin, Anastasi Gavilá, Joaquín Escrivá de Romaní, Santiago Perelló, Antonia Hernando, Cristina Lahuerta, Ainhara Zamora, Pilar Reyes, Victoria Alcalde, María Masanas, Helena Celiz, Pamela Ruiz, Isabel Gil Gil, Miguel Seguí, Miquel A. Peña, Lorena de la
author	Bellet Ezquerra, Meritxell
author_facet	Bellet Ezquerra, Meritxell Ahmad, Faten Villanueva, Rafael Valdivia, Carolina Palomino Doza, Julián Ruiz, Ada Gonzalez-Farre, Xavier Adrover, Encarna Azaro, Analía Valls Margarit, Maria Parra, Josep Lluís Aguilar Company, Juan Vidal Losada, Maria Jesús Martin, Anastasi Gavilá, Joaquín Escrivá de Romaní, Santiago Perelló, Antonia Hernando, Cristina Lahuerta, Ainhara Zamora, Pilar Reyes, Victoria Alcalde, María Masanas, Helena Celiz, Pamela Ruiz, Isabel Gil Gil, Miguel Seguí, Miquel A. Peña, Lorena de la
author_role	author
author2	Ahmad, Faten Villanueva, Rafael Valdivia, Carolina Palomino Doza, Julián Ruiz, Ada Gonzalez-Farre, Xavier Adrover, Encarna Azaro, Analía Valls Margarit, Maria Parra, Josep Lluís Aguilar Company, Juan Vidal Losada, Maria Jesús Martin, Anastasi Gavilá, Joaquín Escrivá de Romaní, Santiago Perelló, Antonia Hernando, Cristina Lahuerta, Ainhara Zamora, Pilar Reyes, Victoria Alcalde, María Masanas, Helena Celiz, Pamela Ruiz, Isabel Gil Gil, Miguel Seguí, Miquel A. Peña, Lorena de la
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	Càncer de mama Oncologia Breast cancer Oncology
topic	Càncer de mama Oncologia Breast cancer Oncology
description	Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.
publishDate	2019
dc.date.none.fl_str_mv	2019
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	https://hdl.handle.net/2445/171556
url	https://hdl.handle.net/2445/171556
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.relation.none.fl_str_mv	Reproducció del document publicat a: https://doi.org/10.1177/1758835919833867 Therapeutic Advances in Medical Oncology, 2019, vol. 11 https://doi.org/10.1177/1758835919833867
dc.rights.none.fl_str_mv	cc by-nc (c) Bellet et al., 2019 http://creativecommons.org/licenses/by-nc/3.0/es/ info:eu-repo/semantics/openAccess
rights_invalid_str_mv	cc by-nc (c) Bellet et al., 2019 http://creativecommons.org/licenses/by-nc/3.0/es/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Sage Publications Ltd.
publisher.none.fl_str_mv	Sage Publications Ltd.
dc.source.none.fl_str_mv	Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) reponame:Dipòsit Digital de la UB instname:Universidad de Barcelona
instname_str	Universidad de Barcelona
reponame_str	Dipòsit Digital de la UB
collection	Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869403579520909312
score	15,300719

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Similares en LA Referencia